Department of Health Care Management, Technische Universität Berlin, Straße des 17. Juni 135, 10623, Berlin, Germany.
Berlin Centre for Health Economics Research (BerlinHECOR), Technische Universität Berlin, Straße des 17. Juni 135, 10623, Berlin, Germany.
Implement Sci. 2021 Oct 30;16(1):94. doi: 10.1186/s13012-021-01159-3.
Innovative medical technologies are commonly associated with positive expectations. At the time of their introduction into care, there is often little evidence available regarding their benefits and harms. Accordingly, some innovative medical technologies with a lack of evidence are used widely until or even though findings of adverse events emerge, while others with study results supporting their safety and effectiveness remain underused. This study aims at examining the diffusion patterns of innovative medical technologies in German inpatient care between 2005 and 2017 while simultaneously considering evidence development.
Based on a qualitatively derived typology and a quantitative clustering of the adoption curves, a representative sample of 21 technologies was selected for further evaluation. Published scientific evidence on efficacy/effectiveness and safety of the technologies was identified and extracted in a systematic approach. Derived from a two-dimensional classification according to the degree of utilization and availability of supportive evidence, the diffusion patterns were then assigned to the categories "Success" (widespread/positive), "Hazard" (widespread/negative), "Overadoption" (widespread/limited or none), "Underadoption" (cautious/positive), "Vigilance" (cautious/negative), and "Prudence" (cautious/limited or none).
Overall, we found limited evidence on the examined technologies regarding both the quantity and quality of published randomized controlled trials. Thus, the categories "Prudence" and "Overadoption" together account for nearly three-quarters of the years evaluated, followed by "Success" with 17%. Even when evidence is available, the transfer of knowledge into practice appears to be inhibited.
The successful implementation of safe and effective innovative medical technologies into practice requires substantial further efforts by policymakers to strengthen systematic knowledge generation and translation. Creating an environment that encourages the conduct of rigorous studies, promotes knowledge translation, and rewards innovative medical technologies according to their added value is a prerequisite for the diffusion of valuable health care.
创新性医疗技术通常伴随着积极的期望。在将其引入临床应用时,关于其益处和危害的证据往往很少。因此,一些缺乏证据的创新性医疗技术在出现不良事件发现之前或之后被广泛使用,而另一些具有支持其安全性和有效性的研究结果的技术则未得到充分使用。本研究旨在考察 2005 年至 2017 年期间德国住院医疗中创新性医疗技术的扩散模式,同时考虑证据的发展。
基于定性推导的分类法和采用曲线的定量聚类,选择了 21 种有代表性的技术进行进一步评估。采用系统方法,确定并提取了技术在疗效/有效性和安全性方面的已发表科学证据。根据利用程度和支持性证据的可用性进行二维分类,将扩散模式分配到“成功”(广泛/积极)、“危险”(广泛/消极)、“过度采用”(广泛/有限或无)、“采用不足”(谨慎/积极)、“警惕”(谨慎/消极)和“谨慎”(谨慎/有限或无)这几类。
总体而言,我们发现,在所检查的技术方面,关于已发表的随机对照试验的数量和质量的证据都很有限。因此,“谨慎”和“过度采用”这两个类别占评估年份的近四分之三,其次是“成功”占 17%。即使有证据可用,知识向实践的转移似乎也受到了抑制。
要将安全有效的创新性医疗技术成功地实施到实践中,政策制定者需要做出更多努力,以加强系统的知识生成和转化。创造一个鼓励进行严格研究、促进知识转化、并根据其附加值奖励创新性医疗技术的环境,是推广有价值医疗保健的前提。